株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃潰瘍 : パイプライン製品の分析

Gastric Ulcers - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 246014
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
胃潰瘍 : パイプライン製品の分析 Gastric Ulcers - Pipeline Review, H2 2017
出版日: 2017年09月19日 ページ情報: 英文 45 Pages
概要

胃潰瘍は胃の内壁における有痛性のびらんまたは潰瘍です。胃潰瘍の最も一般的な原因はヘリコバクター・ピロリ菌感染です。症状には疼痛、腫脹感、吐き気、悪心または嘔吐、および原因不明の体重減少です。素因には喫煙およびアルコール依存などが含まれます。治療には抗生物質および制酸剤などが用いられます。

当レポートでは、胃潰瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

胃潰瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • 開発中の治療薬:企業別
  • 開発中の製品:企業別

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • アステラス製薬
  • Boryung Pharmaceutical Co Ltd
  • ChoDang Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • RaQualia Pharma Inc
  • XuanZhu Pharma Co Ltd

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9721IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2017, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4 and 6 respectively.

Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastric Ulcers - Overview
    • Gastric Ulcers - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Gastric Ulcers - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gastric Ulcers - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Boryung Pharmaceutical Co Ltd
    • ChoDang Pharm Co Ltd
    • Daewoong Pharmaceutical Co Ltd
    • Kukje Pharmaceutical Industry Co Ltd
    • RaQualia Pharma Inc
    • XuanZhu Pharma Co Ltd
  • Gastric Ulcers - Drug Profiles
    • (lafutidine + irsogladine maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anaprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholesteryl glucoside - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1386 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-14012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KJ-14001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SFR-9X0123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Gastric Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tegoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastric Ulcers - Dormant Projects
  • Gastric Ulcers - Discontinued Products
  • Gastric Ulcers - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
      • Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
      • Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
      • Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
      • Oct 23, 2001: Prilosec US litigation
      • May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
      • May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
      • Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
      • Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
      • Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastric Ulcers, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Gastric Ulcers - Pipeline by Astellas Pharma Inc, H2 2017
  • Gastric Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
  • Gastric Ulcers - Pipeline by ChoDang Pharm Co Ltd, H2 2017
  • Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017
  • Gastric Ulcers - Pipeline by RaQualia Pharma Inc, H2 2017
  • Gastric Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
  • Gastric Ulcers - Dormant Projects, H2 2017
  • Gastric Ulcers - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Gastric Ulcers, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top